Discounted Cash Flow Rating

Buy

Return on Equity Rating

Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Altimmune, Inc. Common Stock (ALT)

Pharmaceutical Preparations

https://www.altimmune.com

Altimmune Inc is engaged on developing treatments for obesity and liver diseases. The Company's pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

910 CLOPPER ROAD, SUITE 201S
GAITHERSBURG, MD

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/06/2005

Market Cap

451,647,014

Shares Outstanding

53,730,000

Weighted SO

53,728,871

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

RVPH --.--%

ATHA --.--%

FBIO --.--%

ACAD --.--%

CABA --.--%

AKRO --.--%

TERN --.--%

MDGL --.--%

INZY --.--%

Beta

0.1140

Last Div

0.0000

Range

2.09-14.84

Chg

0.1300

Avg Vol

3376461

Mkt Cap

451647014

Exch

NASDAQ

Country

US

Phone

240 654 1450

DCF Diff

3.8454

DCF

2.5146

Div Yield

0.0000

P/S

1104.2714

EV Multiple

-4.1621

P/FV

2.9619

Div Yield %

0.0000

P/E

-4.4579

PEG

-0.5379

Payout

0.0000

Current Ratio

11.2957

Quick Ratio

11.2957

Cash Ratio

3.7723

DSO

2687.9707

DIO

0.0000

Op Cycle

2687.9707

DPO

47.9859

CCC

2639.9847

Gross Margin

-48.9902

Op Margin

-237.8557

Pretax Margin

-247.7897

Net Margin

-247.7897

Eff Tax Rate

-0.0237

ROA

-0.5846

ROE

-0.6051

ROCE

-0.6150

NI/EBT

1.0000

EBT/EBIT

1.0418

EBIT/Rev

-237.8557

Debt Ratio

0.0020

D/E

0.0023

LT Debt/Cap

0.0000

Total Debt/Cap

0.0023

Int Coverage

3603.0741

CF/Debt

-207.2029

Equity Multi

1.1365

Rec Turnover

0.1358

Pay Turnover

7.6064

Inv Turnover

0.0000

FA Turnover

0.8468

Asset Turnover

0.0024

OCF/Share

-1.0079

FCF/Share

-1.0079

Cash/Share

2.3257

OCF/Sales

-174.7800

FCF/OCF

1.0000

CF Coverage

-207.2029

ST Coverage

-207.2029

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

2.9619

P/B

2.9619

P/S

1104.2714

P/E

-4.4579

P/FCF

-6.3181

P/OCF

-6.3200

P/CF

-6.3200

PEG

-0.5379

P/S

1104.2714

EV Multiple

-4.1621

P/FV

2.9619

DPS

0.0000

Latest Headlines (EST)

Benzinga Jul 19, 18:30 ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm The Motley Fool Dec 19, 23:35 Why Altimmune Was Such a Robustly Healthy Stock on Thursday GlobeNewswire Inc. Nov 07, 01:06 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NBR, PALT, CGBD on Behalf of Shareholders GlobeNewswire Inc. Nov 05, 23:47 SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Altair Engineering Inc. – ALTR GlobeNewswire Inc. Jun 23, 17:45 Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions GlobeNewswire Inc. Jun 22, 20:45 Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions GlobeNewswire Inc. Jun 14, 06:00 Mise à jour : principaux actifs et stratégies GlobeNewswire Inc. Jun 14, 06:00 Update on Core Assets and Strategies GlobeNewswire Inc. Jun 12, 06:00 Tonner Drones publie son rapport annuel et ses comptes audités pour 2023, et convoque l'assemblée générale des actionnaires GlobeNewswire Inc. Jun 12, 06:00 Tonner Drones Publishes 2023 Annual Report and Audited Accounts & Convenes Shareholders’ Annual Meeting GlobeNewswire Inc. May 23, 06:00 Tonner Drones participera au Midcap Event GlobeNewswire Inc. May 23, 06:00 Tonner Drones will join Midcap Event in Paris GlobeNewswire Inc. Jan 22, 16:30 Alta Equipment Group Appoints Jeff Hoover as Chief Legal Officer and General Counsel The Motley Fool Jan 17, 05:10 Livent Merges With Allkem to Become Arcadium Lithium -- Is the Stock a Top Buy for 2024? GlobeNewswire Inc. Jan 02, 07:30 Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024 Investing.com Dec 28, 14:43 Synopsys Offers to Acquire Ansys, Sparks Stock Surge Investing.com Dec 28, 14:43 Synopsys Offers to Acquire Ansys, Sparks Stock Surge Zacks Investment Research Dec 25, 04:00 Bull of the Day: Fluor (FLR) Zacks Investment Research Dec 25, 04:00 Bull of the Day: Fluor (FLR) MarketWatch Dec 23, 13:14 Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk? 

Revenue Product Segmentation

Dividend History

Cash Value Ex-Dividend Date Declaration Date Record Date Pay Date
291.00 01/20/2017 11/30/-0001 01/24/2017 02/03/2017